Prominent players operating in the pulmonary drug delivery devices market include Teva Pharmaceutical Industries Ltd. (Israel), GlaxoSmithKline (U.K.), Boehringer Ingelheim GmbH (Germany), 3M (U.S.), AstraZeneca plc (U.K.), Merck & Co., Inc. (U.S.), Novartis AG (Switzerland), Omron Corporation (Japan), and Sunovion Pharmaceuticals Inc. (U.S.). The majority of the companies operating in this market focused on various organic and inorganic growth strategies, such as collaborations, product launches, approvals, expansions, and acquisitions.
Collaborations accounted for the largest share of the total number of strategies followed by the market players between 2013 and 2016. Major players that adopted this growth strategy include 3M (U.S.), Boehringer Ingelheim (Germany), and Novartis AG (Switzerland). For instance, in June 2016, Boehringer Ingelheim collaborated with the Harvard Stem Cell Institute’s Harvard Fibrosis Network to discover new ways of treating fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF), chronic kidney disease (CKD), and nonalcoholic steatohepatitis (NASH).
Teva is the leading players in the pulmonary drug delivery market due to its broad product portfolio and wide geographic presence. The company pursues various organic and inorganic strategies to further strengthen its foothold in the market. The company has increased its focus on developing new therapeutic entities and complex generics. This has enabled the company to secure a robust position in the market.
3M is the second leading company that focuses on various organic and inorganic growth strategies such as product launches and collaborations to strengthen its position in the market. For instance, in April 2016, 3M Drug Delivery Systems launched the Intelligent Control Inhaler for patients suffering from respiratory diseases. The inhaler delivers accurate doses to patients and provides on-screen instructions for the patient and healthcare provider through an app. In August 2014, 3M Drug Delivery Systems collaborated with Presspart Group (U.K.). Presspart is now a licensed distributor of the 3M Dose by Dose Counter and Dose Indicator, adding to its expanding portfolio of capabilities with metered dose inhaler (MDI) actuators.
Apart from this, In January 2016, Novartis collaborated with Qualcomm Incorporated (U.S.) through its subsidiary, Qualcomm Life, Inc. Under this collaboration, Qualcomm Life will provide a technology solution for the connectivity of the next generation of the Breezhaler inhaler, a device used for Novartis’s portfolio of COPD treatments.
Pulmonary/ Respiratory Drug Delivery Market by Formulation (Type (Solution, Suspension, Dry powder), Device Type (Metered dose, Dry Powder, Nebulizer)), Canister (Plain, Coated), End User (Hospitals, Homecare), Applications (COPD) - Forecasts to 2021
MarketsandMarkets™ Research Pvt. Ltd.
Tower B5, office 101,
Email: [email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE